肺炎球菌疫苗接种后鼻窦炎相关医疗服务利用:低抗体滴度患者分析
本研究为回顾性队列研究,纳入2011年1月至2019年12月938例18-65岁慢性鼻窦炎(CRS)或复发性急性鼻窦炎(RARS)患者,其中75.8%的CRS和74.8%的RARS患者肺炎球菌抗体滴度无保护性,306例低滴度患者接种23价肺炎球菌多糖疫苗(PPSV23)后,89%的CRS和90.1%的RARS患者产生保护性应答;在217例有连续2年接种前后数据的患者中,接种后鼻窦炎就诊诊断次数和抗生素、皮质类固醇处方频率均显著下降。
要点
- CRS和RARS患者中多数肺炎球菌抗体滴度无保护性,分别为75.8%和74.8%。
- 接种PPSV23后89%的CRS和90.1%的RARS患者产生保护性抗体应答。
- 217例有连续数据的患者接种后鼻窦炎就诊和抗生素、皮质类固醇处方显著减少。
核心结论
- 大多数CRS和RARS患者肺炎球菌抗体滴度无保护性,PPSV23接种显著减少医疗服务利用。
研究设计与样本
- 回顾性队列研究,纳入2011年1月至2019年12月期间938例18至65岁、诊断为CRS或RARS且有肺炎球菌滴度数据的患者。
- 排除需在65岁前接种PPSV23的免疫缺陷及共病患者。
主要发现
- CRS患者中75.8%存在无保护性抗体滴度,RARS患者中为74.8%。
- 306例抗体滴度不足的患者接种了PPSV23,其中89%的CRS和90.1%的RARS患者产生保护性应答。
- 在217例有接种前2年至接种后2年连续数据的患者中,CRS就诊诊断次数下降(p < 0.0001),RARS就诊诊断次数下降(p = 0.0006)。
- 抗生素处方频率下降(p = 0.002),皮质类固醇处方频率下降(p = 0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal antibody deficiency has been the subject of limited study in chronic rhinosinusitis (CRS) and has not been studied in recurrent acute rhinosinusitis (RARS). The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is considered for patients with nonprotective Streptococcus pneumoniae titers. We hypothesized that both RARS and CRS patients with deficient S pneumoniae titers and subsequent PPSV23 vaccination would have reduced health-care encounters for sinusitis and fewer prescriptions for antibiotics or steroids. METHODS: A retrospective cohort study was performed of patient encounters between January 2011 and December 2019. All patients included were ≥18 and ≤65 years old with a diagnosis of CRS or RARS and pneumococcal titer data. Patients with immunodeficiency and comorbid conditions requiring PPSV23 vaccination before 65 years of age were excluded. RESULTS: A total of 938 patients were included in the study. Nonprotective antibody titers were present in 75.8% of CRS and 74.8% of RARS patients. A total of 306 patients with deficient antibody titers received the PPSV23 vaccine. Eighty-nine percent of CRS and 90.1% of RARS patients had protective responses. Among the 217 patients with continuous data from 2 years before through 2 years after PPSV23 vaccination, a decrease in the number of encounter diagnoses of CRS (p < 0.0001) and RARS (p = 0.0006) was observed. Decreases in the frequency of antibiotic (p = 0.002) and corticosteroid (p = 0.04) prescriptions were also appreciated. CONCLUSION: Most patients with CRS and RARS have nonprotective antibody titers. PPSV23 administration significantly decreases health-care utilization.
引用
- Bareiss AK, Kattar N, Tivis R, et al. Health-care utilization for sinusitis after pneumococcal vaccination in patients with low antibody titers. Int Forum Allergy Rhinol. 2022. PMID: 34962358. doi:10.1002/alr.22954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。